Trial of Plasma Exchange for Severe Crescentic IgA Nephropathy

Status Terminated

Clinical Trial Summary

Crescentic IgA nephropathy (CreIgAN) has a poor prognosis despite aggressive immunosuppressive therapy. The efficacy of plasma exchange (PE) in CreIgAN is not well defined. This study will evaluate the efficacy and safety of plasma exchange as adjunctive therapy for severe crescentic IgA nephropathy compared to pulse methylprednisolone on a background of oral prednisolone and cyclophosphamide in prevent kidney failure.

Clinical Trial Description

IgA nephropathy (IgAN) is one of the most common glomerulonephritides and is characterized by a highly variable clinical course and diverse histopathological lesions. Although most affected individuals develop chronic, slowly progressive renal injury, a subgroup of patients (<5% of all IgAN patients) with diffuse crescent formation, which is termed as crescentic IgA nephropathy (CreIgAN) and often leads to rapidly progressive kidney failure. The recent Kidney Disease: Improving Global Outcomes (KDIGO) guidelines suggest high-dose steroids and cyclophosphamide therapy for CreIgAN. However, this suggestion is mainly based on several small observational studies, and the 1- and 5-year renal survival rates of patients treated with this regimen were as low as 65% and 28%, respectively, in one large cohort of CreIgAN patients. The efficacy of plasma exchange (PE) in severe CreIgAN is not well evaluated, although several anecdotal reports have indicated benefit of PE in combination with immunosuppressive therapies in IgAN patients. Retrospective cohort study in our unite also supported the benefit of PE as additional therapy for CreIgAN patients. However, randomized controlled trial is needed to evaluate the efficacy and safety of plasma exchange as adjunctive therapy for crescentic IgA nephropathy compared to pulse methylprednisolone on a background of oral prednisolone and cyclophosphamide in prevent kidney failure. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02647255
Study type	Interventional
Source	Peking University First Hospital
Contact
Status	Terminated
Phase	Phase 2/Phase 3
Start date	March 2016
Completion date	October 2020

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03246984` - VALUE- Vascular Access Laminate eUropean Experience. A Post Market Surveillance Study to Assess the Safety and Effectiveness of VasQ	N/A
Completed	`NCT03545113` - Graft-first Versus Fistula-first in Older Patients With End-stage Kidney Disease	N/A
Recruiting	`NCT05100017` - Methocarbamol vs Oxybutynin for Management of Pain and Discomfort S/P Ureteroscopy Procedure	N/A
Recruiting	`NCT04559321` - Holmium Vs Trilogy Kidney Stones GUY's 1-2	Phase 3
Recruiting	`NCT05036850` - China Kidney Patient Trials Network
Completed	`NCT04037436` - Functional Exercise and Nutrition Education Program for Older Adults	N/A
Active, not recruiting	`NCT01529658` - Renal Hypothermia During Partial Nephrectomy	N/A
Completed	`NCT01679587` - Dose Escalation Study to Investigate Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of BAY85-3934 in Subjects With Chronic Kidney Disease (CKD)	Phase 1
Completed	`NCT01155141` - Idiopathic Focal Segmental Glomerulosclerosis (FSGS) and Treatment With ACTH	Phase 4
Completed	`NCT00755690` - Study of Dietary Phosphate and Mineral Homeostasis in Early Chronic Kidney Disease	N/A
Recruiting	`NCT05759754` - Effects of Traditional Chinese Medicine (GSJYF) in Children With Inherited Proteinuric Kidney Disease	N/A
Completed	`NCT03213158` - Ixazomib for Desensitization	Phase 2
Active, not recruiting	`NCT02237352` - Mechanisms of Diabetic Nephropathy in Ecuador
Recruiting	`NCT06067867` - Kidney and Pregnancy Registry
Recruiting	`NCT04110080` - Enhanced Recovery After Surgery in Kidney Transplant Donors	N/A
Active, not recruiting	`NCT04876963` - HOLT-ED: Holter-monitoring in End-stage Renal Disease
Enrolling by invitation	`NCT05324878` - Honoring Individual Goals and Hopes: Implementing Advance Care Planning for Persons With Kidney Disease on Dialysis
Not yet recruiting	`NCT03899298` - Safety and Clinical Outcomes With Amniotic and Umbilical Cord Tissue Therapy for Numerous Medical Conditions	Phase 1
Active, not recruiting	`NCT04631965` - Healthcare Transition of Adolescents With Chronic Health Conditions
Completed	`NCT03394859` - Electronic Medical Records and Genomics (eMERGE) Phase III

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Trial of Plasma Exchange for Severe Crescentic IgA Nephropathy — RESCUE

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms